Welcome to the international HTA database

Showing [16861 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2021	Scottish Medicines Consortium (SMC)	Entrectinib for the treatment of patients with ROS1-positive, advanced non-small-cell lung cancer (NSCLC) not previously treated with ROS-1 inhibitors
2021	Health Technology Wales (HTW)	Strategies for Relatives (START) intervention to improve the mental health of carers of people with dementia
2021	Health Information and Quality Authority (HIQA)	Rolling summary of the evidence in relation to the Omicron (B.1.1.529) variant
2021	National Institute for Health and Care Excellence (NICE)	Upadacitinib for treating moderate rheumatoid arthritis. NICE technology appraisal guidance 744
2021	NIHR Health Technology Assessment programme	A comparison of general anaesthesia versus awake-regional anaesthesia in infancy: an international, multicentre, randomised controlled equivalence trial; the GAS study
2021	NIHR Health Technology Assessment programme	Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs
2021	Belgian Health Care Knowledge Centre (KCE)	Remote monitoring of patients with cardiovascular implantable electronic devices: a health technology assessment (update of the KCE Report 136)
2021	Health Information and Quality Authority (HIQA)	Use of respirator masks by persons who are at higher risk from COVID-19
2021	National Institute for Health and Care Excellence (NICE)	NBTXR-3 for treating advanced soft tissue sarcoma (terminated appraisal). NICE technology appraisal guidance 745
2021	Health Council of the Netherlands Gezondheidsraad (GR)	[Influenza vaccination: review of indications]
2021	Health Information and Quality Authority (HIQA)	Rapid review of public health guidance for residential care facilities in the context of COVID-19
2021	National Institute for Health and Care Excellence (NICE)	Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer. NICE technology appraisal guidance 746
2021	Austrian Institute for Health Technology Assessment (AIHTA)	Long COVID care pathways: a systematic review
2021	WorkSafeBC	Causal association between care aide work and the development of carpal tunnel syndrome (CTS)
2021	National Institute for Health and Care Excellence (NICE)	Nintedanib for treating progressive fibrosing interstitial lung diseases. NICE technology appraisal guidance 747
2021	Center for Drug Evaluation (CDE)	Real-world results of immune checkpoint inhibitors from the Taiwan National Health Insurance Registration System
2021	Canadian Agency for Drugs and Technologies in Health (CADTH)	Autologous hematopoietic cell transplant for patients with multiple sclerosis
2021	WorkSafeBC	Acupuncture or massage therapy as treatment for occipital neuralgia
2021	National Institute for Health and Care Excellence (NICE)	Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders. NICE technology appraisal guidance 748
2021	Adelaide Health Technology Assessment (AHTA)	Guidelines for preparing assessments for the Medical Services Advisory Committee. Version 1.0
2021	Center for Drug Evaluation (CDE)	Effects of direct-acting antiviral therapy for patients with advanced hepatocellular carcinoma and concomitant hepatitis C-A population-based cohort study
2021	National Institute for Health and Care Excellence (NICE)	Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal). NICE technology appraisal guidance 749
2021	Health Technology Wales (HTW)	Oscillating positive expiratory pressure devices for airway clearance in chronic hypersecretory lung conditions
2021	Adelaide Health Technology Assessment (AHTA)	Immunoglobulin for chronic inflammatory demyelinating polyneuropathy
2021	National Institute for Health and Care Excellence (NICE)	Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal). NICE technology appraisal guidance 750
2021	NIHR Health Technology Assessment programme	Prognostic biomarkers to identify patients likely to develop severe Crohn’s disease: a systematic review
2021	Adelaide Health Technology Assessment (AHTA)	Genomic testing for the diagnosis of heritable cardiomyopathies
2021	National Institute for Health and Care Excellence (NICE)	Dupilumab for treating severe asthma with type 2 inflammation. NICE technology appraisal guidance 751
2021	National Institute for Health and Care Excellence (NICE)	Belimumab for treating active autoantibody-positive systemic lupus erythematosus. NICE technology appraisal guidance 752
2021	National Institute for Health and Care Excellence (NICE)	Cenobamate for treating focal onset seizures in epilepsy. NICE technology appraisal guidance 753
2021	National Institute for Health and Care Excellence (NICE)	Mogamulizumab for previously treated mycosis fungoides and Sezary syndrome. NICE technology appraisal guidance 754
2021	National Institute for Health and Care Excellence (NICE)	Risdiplam for treating spinal muscular atrophy. NICE technology appraisal guidance 755
2021	National Institute for Health and Care Excellence (NICE)	Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis. NICE technology appraisal guidance 756
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Palliative care screening tools
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Procalcitonin for antimicrobial discontinuation in hospitalized adult patients
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Prone positioning of patients on extracorporeal membrane oxygenation (ECMO)
2021	Health Information and Quality Authority (HIQA)	Duration of immunity (protection from reinfection) following SARS-CoV-2 infection
2021	NIHR Health Services and Delivery Research programme	Hospital-based specialist palliative care compared with usual care for adults with advanced illness and their caregivers: a systematic review
2021	NIHR Health Technology Assessment programme	Optimal surveillance strategies for patients with stage 1 cutaneous melanoma post primary tumour excision: three systematic reviews and an economic model
2021	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: thrombotic adverse events with adenovirus vaccines
2021	NIHR Health Technology Assessment programme	High-sensitivity troponin assays for early rule-out of acute myocardial infarction in people with acute chest pain: a systematic review and economic evaluation
2021	Austrian Institute for Health Technology Assessment (AIHTA)	National strategies and programmes for preventing and managing non-communicable diseases in selected countries
2021	Malaysian Health Technology Assessment (MaHTAS)	Targeted therapies in combination with neoadjuvant chemotherapy for HER2-positive breast cancer and economic evaluation
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Tracheostomy or endotracheal tubes and subglottic suctioning
2021	Malaysian Health Technology Assessment (MaHTAS)	Therapeutic drug monitoring (TDM) for anti-tuberculosis
2021	NIHR Health Technology Assessment programme	Modelling tool to support decision-making in the NHS Health Check programme: workshops, systematic review and co-production with users
2021	Health Information and Quality Authority (HIQA)	Review of international ethics frameworks used in policy-making in the context of screening
2021	Malaysian Health Technology Assessment (MaHTAS)	Custodiol HTK as a replacement of blood cardioplegia in cardiac surgery
2021	Canadian Agency for Drugs and Technologies in Health (CADTH)	Prevention of tuberculosis reactivation
2021	Malaysian Health Technology Assessment (MaHTAS)	Mobile C-arm fluoroscopy for cardiothoracic surgery
2021	NIHR Health Technology Assessment programme	Cognitive therapy compared with CBT for social anxiety disorder in adolescents: a feasibility study
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Opioids for vaso-occlusive crisis in pregnant patients
2021	NIHR Health Technology Assessment programme	Improving continence in children and young people with neurodisability: a systematic review and survey
2021	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: vaccination for women who are pregnant or lactating
2021	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: management of vaccine-associated thrombotic syndromes
2021	Swiss Federal Office of Public Health (FOPH)	Effectiveness and safety of vitamin B12 tests
2021	Canadian Agency for Drugs and Technologies in Health (CADTH)	Yttrium-90 microspheres for intermediate- or advanced-stage hepatocellular carcinoma
2021	Malaysian Health Technology Assessment (MaHTAS)	Viscoelastic haemostatic assay for non-cardiac surgery
2021	Health Information and Quality Authority (HIQA)	The identification and review of new and updated public health guidance - COVID-19
2021	NIHR Health Technology Assessment programme	CONservative TReatment of Appendicitis in Children a randomised controlled Trial CONTRACT (Feasibility study)
2021	Health Information and Quality Authority (HIQA)	Duration of protective immunity following COVID-19 vaccination (efficacy and effectiveness)
2021	NIHR Health Services and Delivery Research programme	Acute day units in non-residential settings for people in mental health crisis: the AD-CARE mixed-methods study
2021	Canadian Agency for Drugs and Technologies in Health (CADTH)	Abiraterone acetate for metastatic castration-sensitive prostate cancer
2021	Canadian Agency for Drugs and Technologies in Health (CADTH)	Remote monitoring programs for cardiac conditions
2021	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: effects of vaccines on fertility and pregnancy outcomes
2021	Canadian Agency for Drugs and Technologies in Health (CADTH)	Bisphosphonate drugs for the treatment of osteoporosis in post-menopausal women
2021	Canadian Agency for Drugs and Technologies in Health (CADTH)	Direct oral anticoagulants for atrial fibrillation [evidence update]
2021	Canadian Agency for Drugs and Technologies in Health (CADTH)	Interventions to address and prevent violence toward health care workers in the emergency department
2021	Health Information and Quality Authority (HIQA)	An international review: Policies relating to healthcare personnel who do not avail of COVID-19 vaccination
2021	NIHR Health Technology Assessment programme	Understanding health-care outcomes of older people with cognitive impairment and/or dementia admitted to hospital: a mixed-methods study
2021	NIHR Health Technology Assessment programme	Antidepressant medication to prevent depression relapse in primary care: the ANTLER RCT
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Amikacin (Mycobacterium avium complex pulmonary infections)]
2021	Canadian Agency for Drugs and Technologies in Health (CADTH)	Hybrid closed-loop insulin delivery systems for people with Type 1 diabetes
2021	Health Technology Wales (HTW)	Transcranial magnetic stimulation for the treatment of depression
2021	Health Information and Quality Authority (HIQA)	Evidence synthesis for groups in vaccine allocation group nine - those aged 18-64 years living or working in crowded conditions
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Atidarsagen autotemcel (metachromatic leukodystrophy with biallelic mutation in the ARSA gene)]
2021	Health Information and Quality Authority (HIQA)	Advice to the National Public Health Emergency Team: Derogation of healthcare workers, who are deemed close contacts, from restricted movements following COVID-19 vaccination
2021	NIHR Health Services and Delivery Research programme	Models of generalist and specialist care in smaller acute hospitals: an exploratory study
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: noninvasive fetal RhD genotyping using maternal plasma]
2021	Scottish Health Technologies Group (SHTG)	Detection of paroxysmal atrial fibrillation in patients with newly diagnosed ischaemic stroke
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Autologous anti-CD19-transduced CD3+ cells (mantle cell lymphoma, pretreated patients)]
2021	Health Information and Quality Authority (HIQA)	Public health measures and strategies to limit the spread of COVID-19: an international review [Update]
2021	The Federal Joint Committee (G-BA)	[Pharamceutical Directive/Annex XII: Avapritinib (gastrointestinal stromal tumours)]
2021	Health Information and Quality Authority (HIQA)	Public health measures and strategies to limit the spread of COVID-19: an international review: Antigen testing in asymptomatic individuals in community settings
2021	Health Information and Quality Authority (HIQA)	Current public health guidance for community settings and infection prevention and control measures in healthcare settings for COVID-19: a rapid review
2021	Canadian Agency for Drugs and Technologies in Health (CADTH)	Stereotactic ablative radiotherapy for the treatment of oligometastatic cancer: a clinical review as part of a health technology assessment v1.0
2021	Swiss Federal Office of Public Health (FOPH)	Statins in the primary prevention of cardiovascular events and mortality in Switzerland
2021	NIHR Health Technology Assessment programme	Testing strategies for Lynch syndrome in people with endometrial cancer: systematic reviews and economic evaluation
2021	Swiss Federal Office of Public Health (FOPH)	Vertebroplasty or kyphoplasty in painful osteoporotic vertebral compression fractures unresponsive to non-surgical treatment
2021	Swiss Federal Office of Public Health (FOPH)	Chondroitin sulfate in osteoarthritis
2021	Malaysian Health Technology Assessment (MaHTAS)	Platelet rich plasma, platele-rich fibrin (PRF) and concentrated growth factor (CGF) for treatment of periodontal disease
2021	NIHR Health Technology Assessment programme	Paclitaxel-assisted balloon angioplasty of venous stenosis in haemodialysis access: PAVE RCT
2021	Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS)	[Identification of factors influencing the risk of absconding in a user with an intellectual disability, autism spectrum disorder or a mental health disorder]
2021	The Regional Health Technology Assessment Centre (HTA-centrum)	Clinical effects of preoperative i.v. iron infusion in patients with colorectal cancer and iron-deficiency anemia
2021	The Regional Health Technology Assessment Centre (HTA-centrum)	Clopidogrel versus ticagrelor as part of dual antiplatelet therapy for patients with acute coronary syndrome
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Venous irritation resulting from IV fosaprepitant
2021	The Regional Health Technology Assessment Centre (HTA-centrum)	Efficacy and safety of endovascular versus surgical arteriovenous fistula creation for hemodialysis
2021	NIHR Health Technology Assessment programme	Prospective randomised marker-based trial to assess the clinical utility and safety of biomarker-guided immunosuppression withdrawal in liver transplantation
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Oral hygiene interventions to prevent ventilator-associated pneumonia (VAP)
2021	The Regional Health Technology Assessment Centre (HTA-centrum)	Effectiveness and safety of breast reduction surgery, compared with no surgery, in women with symptomatic breast hypertrophy